Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 5/20 | 0.50 |
| ▸ | HTR2B | P41595 | 5/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL120103 | 0.87 | AGXT (0.55) | AGXTHTR1AHTR2BDRD2LOXL2 | |
| SCHEMBL13960026 | 0.85 | KMT2A (0.57) | AGXTHTR1AHTR2BDRD2LOXL2 | |
| SCHEMBL118984 | 0.82 | NPC1 (0.44) | HTR1AHTR2BDRD2NPC1RAB9A | |
| SCHEMBL7201620 | 0.79 | AGXT (0.57) | AGXTHTR1AHTR2BDRD2LOXL2 | |
| SCHEMBL1746605 | 0.79 | FFAR1 (0.60) | — | |
| SCHEMBL14153179 | 0.78 | RAB9A (0.57) | AGXTHTR1AHTR2BDRD2LOXL2 | |
| SCHEMBL1747344 | 0.76 | PPARG (0.53) | HTR1AHTR2BDRD2ADAMTS4NPC1 | |
| SCHEMBL9043542 | 0.75 | PTPRC (0.57) | AGXTADAMTS4NPC1RAB9A | |
| SCHEMBL119196 | 0.75 | LOXL2 (0.64) | AGXTHTR1AHTR2BDRD2LOXL2 | |
| SCHEMBL17193851 | 0.75 | HTR2B (0.43) | AGXTHTR1AHTR2BDRD2ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691558-A2 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | University Court of The University of Dundee (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2025-09-25 | — | — | US | disclosed |
| EP-2857018-B1 | Treatment or prophylaxis of proliferative conditions | UNIV COURT OF THE UNIV OF DUNDEE (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-20220031852-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2022-02-03 | — | — | US | disclosed |
| US-20200360521-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2020-11-19 | — | — | US | disclosed |
| US-9919060-B2 | Treatment or prophylaxis of proliferative conditions | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2018-03-20 | — | — | US | disclosed |
| US-20170368188-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2017-12-28 | — | — | US | disclosed |
| EP-2857018-A1 | Treatment or prophylaxis of proliferative conditions | University Court of The University of Dundee (GB) | 2015-04-08 | — | — | EP | disclosed |
| US-20150011512-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2015-01-08 | — | — | US | disclosed |
| US-20120302748-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2012-11-29 | — | — | US | disclosed |
| US-8283340-B2 | Treatment or prophylaxis of proliferative conditions | The University of the University of Dundee (GB) | 2012-10-09 | — | — | US | disclosed |
| US-20120190639-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2012-07-26 | — | — | US | disclosed |
| EP-2424524-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | University Court of The University of Dundee (GB) | 2012-03-07 | — | — | EP | disclosed |
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-12-02 | — | — | US | disclosed |
| WO-2010125350-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305070-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | BRCA1, CYP1B1, UGT1A1 | AGXT 2560/4885HTR1A 1572/4885HTR2B 1810/4885 |
| US-20200360521-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | AGXT 2365/4885HTR1A 1218/4885HTR2B 1695/4885 |
| US-20120302748-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | BRCA1, CYP1B1, UGT1A1 | AGXT 2560/4885HTR1A 1572/4885HTR2B 1810/4885 |
| US-20120190639-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | AGXT 2365/4885HTR1A 1218/4885HTR2B 1695/4885 |
| US-20220031852-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | AGXT 2365/4885HTR1A 1218/4885HTR2B 1695/4885 |
| US-20250295789-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, BRCA1, UGT1A1 | AGXT 2494/4885HTR1A 1118/4885HTR2B 1552/4885 |
| US-20170368188-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | AGXT 2505/4885HTR1A 899/4885HTR2B 1218/4885 |
| US-20150011512-A1 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | CYP1B1, UGT1A1, CYP1A1 | AGXT 2365/4885HTR1A 1218/4885HTR2B 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.